荷丹片联合阿托伐他汀对伴有睡眠呼吸暂停的脑梗死患者血脂及炎症因子的影响

Effect of Hedan Tablets combined with Atorvastatin on serum lipids and inflammatory factors in cerebral infarction with sleep apnea-hypopnea patients

目的探讨荷丹片联合阿托伐他汀对伴有睡眠呼吸暂停的脑梗死患者血脂及炎症因子的影响。方法依据多导睡眠图检测结果选取2013年1月~2015年6月于河北大学附属医院就诊的74例伴有睡眠呼吸暂停的脑梗死患者作为研究对象,随机分为对照组和观察组,两组均为37例,对照组给予口服阿托伐他汀,观察组给予口服荷丹片联合阿托伐他汀,两组患者均给药4周,观察治疗前后血清三酰甘油(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、超敏C反应蛋白(hs-CRP)及可溶性细胞间黏附分子1(s ICAM-1)的变化情况。结果观察组及对照组患者治疗后血清TG[(2.549±0.441)、(2.854±0.444)mmol/L]、TC[(2.865±1.035)、(2.992±0.991)mmol/L]、LDL-C[(1.778±0.486)、(1.827±0.527)mmol/L]、hs-CRP[(1.846±0.607)、(2.230±0.799)mg/L]及s ICAM-1[(315.532±39.717)、(345.108±30.733)ng/m L]水平均较治疗前[(3.630±0.548)、(3.862±0.683)mmol/L;(5.878±0.999)、(5.757±1.062)mmol/L;(3.687±0.581)、(3.538±0.658)mmol/L;(4.500±1.432)、(4.422±1.540)mg/L;(397.762±33.752)、(409.243±39.001)ng/m L]显著降低,差异有高度统计学意义(P<0.01)。两组治疗后TC、LDL-C水平比较差异无统计学意义(P>0.05),但观察组治疗后TG、hs-CRP及s ICAM-1水平显著低于对照组,差异有统计学意义(P<0.05或P<0.01)。结论荷丹片联合阿托伐他汀对伴有睡眠呼吸暂停的脑梗死患者有较强的降脂作用,尤其是降TG方面,且增强抗炎作用。

Objective To investigate the effects of Hedan Tablets combined with Atorvastatin for serum lipids and inflammatory factors of cerebral infarction with sleep apnea-hypopnea patients. Methods Total 74 cases of cerebral infarction with sleep apnea-hypopnea patients admitted to the Affiliated Hospital of Hebei University from January 2013 to June 2015 were selected as research objects. The patients were randomly divided into control group(n = 37) and observation group(n = 37). The control group was treated with oral administration of Atorvastatin for 4 weeks, the observation group was treated with oral administration of Hedan Tablets combined with Atorvastatin for 4 weeks. Before and after treatment the serum triglyceride(TG), total cholesterol(TC), low density lipoprotein C(LDL-C), high-sensitivity C-reactive protein(hs-CRP) and soluble intercellular adhesion molecules-1(s ICAM-1) were determined. Results After treatment, the levels of serum TG [(2.549 ±0.441),(2.854 ±0.444) mmol/L], TC [(2.865 ±1.035),(2.992 ±0.991) mmol/L],LDL-C[(1.778±0.486),(1.827±0.527) mmol/L], hs-CRP[(1.846±0.607),(2.230±0.799) mg/L] and s ICAM-1 [(315.532 ±39.717),(345.108 ±30.733) ng/m L] in observation group and control group were all lower than those [(3.630 ±0.548),(3.862±0.683) mmol/L;(5.878±0.999),(5.757±1.062) mmol/L;(3.687±0.581),(3.538±0.658) mmol/L;(4.500±1.432),(4.422±1.540) mg/L;(397.762±33.752),(409.243±39.001) ng/m L] before treatment, the differences were all statistically significant(P < 0.01). After treatment, there were no statistically significant differences of the levels of serum TC and LDLC between observation group and control group(P > 0.05). The levels of serum TG, hs-CRP and s ICAM-1 in control group were lower than those of observation group after treatment, the differences were statistically significant(P < 0.05 or P < 0.01).Conclusion Hedan Tablets combined with atorvastatin has strong effects of lipid-lowering in cerebral infarction with sleep apnea-hypopnea patients. Hedan tablet combined with atorvastatincan strengthens the inflammatory response.